Centre for Women's Mental Health, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, UK.
Division of Informatics, Imaging and Data Science, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, UK; Centre for Pharmacoepidemiology and Drug Safety, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, UK.
J Affect Disord. 2020 May 15;269:141-147. doi: 10.1016/j.jad.2020.03.037. Epub 2020 Mar 20.
Changes in care may mean women with serious mental illness (SMI) are more fertile. We investigated 1) the live-birth and pregnancy rate of women with and without SMI over time, 2) the likelihood of pregnancy when using second or first-generation antipsychotics.
Retrospective cohort study of women (15-45 years) registered in Clinical Practice Research Datalink (CPRD) general practices between 1992 and 2017. Each analysis year, women with SMI (affective and non-affective psychotic disorder) were matched with up to four women with no record of SMI on age, calendar year and general practice. Pregnancy and live-birth rates and the rate ratio (RR) comparing women with and without SMI were estimated. The stability of the RR between years was tested. For women with SMI, the pregnancy rates when on or off first or second-generation antipsychotics were calculated and compared using Poisson regression models.
In total, 12,524 women with SMI were matched to 50,074 women without SMI, median age 34 [IQR 28-39] years. Between 1992 and 2017 women with SMI had 50% fewer live-births than women without SMI (RR 0..50, 95%CI 0.45-0.55). The pregnancy rate ratio increased from 0.64 (95%CI 0.48-0.86) (1992-1994) to 1.00 (95%CI 0.81-1.22) (2016-2017), (p < 0.0001), but this change was only seen in women with affective disorders. Women are most likely to become pregnant after discontinuing either a second-generation or first-generation antipsychotic (RR 1.74, 95%CI 1.42-2.13).
Women with SMI are increasingly experiencing pregnancy but not live-birth, which suggests the reproductive health needs of these women are unmet.
治疗方法的改变可能意味着患有严重精神疾病(SMI)的女性生育能力增强。我们研究了 1)随着时间的推移,患有 SMI 和无 SMI 的女性的活产率和妊娠率;2)使用第二代或第一代抗精神病药物时怀孕的可能性。
这是一项回顾性队列研究,纳入了 1992 年至 2017 年在临床实践研究数据链接(CPRD)普通诊所登记的女性(15-45 岁)。在每个分析年度,将患有 SMI(情感和非情感性精神病障碍)的女性与没有 SMI 记录的女性按年龄、日历年份和普通诊所进行匹配,最多匹配 4 名。估计了有和没有 SMI 的女性的妊娠率和活产率以及比率比(RR)。测试了 RR 多年来的稳定性。对于患有 SMI 的女性,计算并比较了服用第一代或第二代抗精神病药物时的妊娠率,并使用泊松回归模型进行比较。
共有 12524 名患有 SMI 的女性与 50074 名没有 SMI 的女性相匹配,中位年龄为 34[IQR 28-39]岁。在 1992 年至 2017 年间,患有 SMI 的女性活产率比没有 SMI 的女性低 50%(RR 0.50,95%CI 0.45-0.55)。妊娠率比值从 0.64(95%CI 0.48-0.86)(1992-1994 年)增加到 1.00(95%CI 0.81-1.22)(2016-2017 年)(p<0.0001),但这种变化仅见于患有情感障碍的女性。女性最有可能在停止使用第二代或第一代抗精神病药物后怀孕(RR 1.74,95%CI 1.42-2.13)。
患有 SMI 的女性越来越容易怀孕,但活产率却没有增加,这表明这些女性的生殖健康需求未得到满足。